Spirocyclic nonpeptide glycoprotein IIb-IIIa antagonists. Part 2: Design of potent antagonists containing the 3-azaspiro[5.5]undec-9-yl template

Bioorganic and Medicinal Chemistry Letters

Volumn 11, Issue 10, 2001, Pages 1293-1296

  Pandey, A ^a   Seroogy, J ^a   Volkots, D ^a   Smyth, M S ^a   Rose, J ^a   Mehrotra, M M ^a   Heath, J ^a   Ruhter, G ^b   Schotten, T ^b   Scarborough, R M ^a  

^a MILLENNIUM PHARMACEUTICALS INC   (United States)

^b Lilly Research Laboratories   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

3 AZASPIRO[5.5]UNDE 9 YL; BENZAMIDINE DERIVATIVE; CT 51688; FIBRINOGEN RECEPTOR ANTAGONIST; UNCLASSIFIED DRUG; UNDECANOIC ACID;

ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; STRUCTURE ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION;

ADMINISTRATION, ORAL; ANIMALS; AZA COMPOUNDS; BIOLOGICAL AVAILABILITY; BLOOD PLATELETS; HUMANS; INHIBITORY CONCENTRATION 50; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VITRONECTIN; SPIRO COMPOUNDS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0035927195     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(01)00216-5     Document Type: Article

References (12)

1. Scarborough R.M. J. Med. Chem. 43:2000;3453.
2. Scarborough R.M. Curr. Med. Chem. 6:1999;971.
3. Smyth M.S., Rose J., Mehrotra M.M., Heath J., Ruhter G., Schotten T., Seroogy, J., Volkots D., Pandey A., Scarborough R.M. Bioorg. Med. Chem. Lett. 11:2001;1289.
4. Claremont, D. A.; Liverton, N.; Baldwin, J. J. U.S. Patent 5,451,578, 1995; Chem. Abstr. 1995, 124, 145932.
5. Su T., Naughton M.A.H., Smyth M.S., Rose J.W., Arfsten A.E., McCowan J.R., Jakubowski J.A., Wyss V.L., Ruterbories K.J., Sall D.J., Scarborough R.M. J. Med. Chem. 40:1997;4308.
6. Egbertson M.S., Chang C.T.-C., Duggan M.E., Gould R.J., Halczenko W., Hartman G.D., Laswell W.L., Lynch J.J., Lynch R.J., Manno P.D., Naylor A.M., Prugh J.D., Ramjit D.R., Sitko G.R., Smith R.S., Turchi L.M., Zhang G.J. J. Med. Chem. 37:1994;2537.
7. Xue C.-B., Wityak J., Seilecki T.M., Pinto D.J., Batt D.G., Cain G.A., Sworin M., Rockwell A.L., Roderick J.J., Wang S., Orwat M.J., Frietze W.E., Bostrom L.L., Liu J., Higley C.A., Rankin F.W., Tobin A.E., Emmett G., Lalka G.K., Sze J.Y., Di Meo S.V., Mousa S.A., Thoolen M.J., Racanelli A.L., Hausner E.A., Reilly T.M., DeGrado W.F., Wexler R.R., Olsen R.E. J. Med. Chem. 40:1997;2064.
8. Xue C.B., Mousa S.A. Drugs Future. 23:1998;707.
9. Olsen R.E., Sielecki T.M., Wityak J., Pinto D.J., Batt D.G., Frietze W.E., Liu J., Tobin E., Orwat M.J., Di Meo S.V., Houghton G.C., Lalka G.K., Mousa S.A., Racanelli A.L., Hausner E.A., Kapil R.P., Rabel S.R., Thoolen M.J., Reilly T.M., Anderson P.S., Wexler R.R. J. Med. Chem. 42:1999;1178.
10. Mousa S.A., Wityak J. Cardiovas. Drug. Rev. 16:1998;48.
11. Law D.A., Nannizzi-Alaimo L., Cowan K.J., Prasad K.S., Ramakrishnan V., Phillips D.R. Thromb. Haemost. 82(Suppl.):1999;345.
12. Zablocki J.A., Rico J.G., Garland R.B., Rogers T.E., Williams K., Schretzman L.A., Rao S.A., Bovy P.R., Tjoeng D.E., Adams S.P., Miyano M., Markos C.S., Milton M.N., Knodle S.G., Haas N.F., Page J.D., Szalony J.A., Salyers A.K., King L.W., Campion J.G., Feigen L.P. J. Med. Chem. 38:1995;2378.